NYSEAMERICAN:RGNT Regentis Biomaterials Q2 2026 Earnings Results & Report $1.60 0.00 (0.00%) Closing price 10/9/2026 04:10 PM EasternExtended Trading$1.69 +0.09 (+5.37%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Regentis Biomaterials reported Q2 2026 earnings on September 11, 2026. The company reported EPS of -$0.22. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateSeptember 11, 2026TimeBefore Market Opens Regentis Biomaterials EPS ResultsActual EPS-$0.22Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ARegentis Biomaterials Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Regentis Biomaterials Q2 2026 Earnings FAQ Did Regentis Biomaterials beat earnings estimates for Q2 2026? Regentis Biomaterials (NYSEAMERICAN:RGNT) reported earnings of -$0.22 per share for Q2 2026. The report was announced on Friday, September 11, 2026. Regentis Biomaterials Earnings HeadlinesRegentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage CareSeptember 29, 2026 | theglobeandmail.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.September 18, 2026 | globenewswire.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need. | Investors Alley (Ad)Regentis Biomaterials (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage RepairSeptember 14, 2026 | markets.businessinsider.comRegentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage RepairSeptember 14, 2026 | finance.yahoo.comRegentis Biomaterials Ltd: Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate UpdateSeptember 11, 2026 | finanznachrichten.deSee More Regentis Biomaterials Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Regentis Biomaterials? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regentis Biomaterials and other key companies, straight to your email. Email Address About Regentis BiomaterialsRegentis Biomaterials (NYSEAMERICAN:RGNT) is an Israel-based biotechnology company focused on developing biomaterial-based solutions for the repair and regeneration of damaged cartilage. The company’s work is aimed primarily at orthopedic applications, including the treatment of focal cartilage defects in the knee. Regentis’ lead product is GelrinC, a synthetic, cell-free hydrogel implant designed to fill cartilage lesions and support the formation of new tissue. The implant is intended to be delivered during a minimally invasive procedure and gradually integrate with the surrounding joint environment as the repair process progresses. The company’s activities center on research, clinical development, regulatory advancement and potential commercialization of its cartilage-repair technology. Regentis Biomaterials is headquartered in Israel and has pursued development for international orthopedic markets. Publicly available information about its broader product pipeline and current leadership is limited.View Regentis Biomaterials ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
